	Ų
7	`
0	n
_	7

# Notice of Allowability

Application No.	Applicant(s)
09/902,540	GOLDMAN ET AL.
Examiner	Art Unit
Carolyn L Smith	1631

ı						
		Carolyn L Smith	1631	<u></u>		
	The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIG	(OR REMAINS) CLOSED in this appropriate communication  GHTS. This application is subject to	lication. If not include	ed		
	1. X This communication is responsive to 7/12/04.					
2. The allowed claim(s) is/are 11, 43, 44, 45, and 46, renumbered 1, 2, 3, 4, and 5, respectively.						
	3. The drawings filed on are accepted by the Examiner.					
	<ul> <li>4. ☐ Acknowledgment is made of a claim for foreign priority und</li> <li>a) ☐ All b) ☐ Some* c) ☐ None of the:</li> <li>1. ☐ Certified copies of the priority documents have</li> <li>2. ☐ Certified copies of the priority documents have</li> </ul>	been received.				
	<ol> <li>Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).</li> </ol>					
	* Certified copies not received:  Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.					
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.						
	<ul> <li>6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.</li> <li>(a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached</li> <li>1) hereto or 2) to Paper No./Mail Date</li> <li>(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date</li> </ul>					
	Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).					
	7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.					
	Attachment(s)  1. ☐ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08) Paper No./Mail Date  4. ☐ Examiner's Comment Regarding Requirement for Deposit	5. ☐ Notice of Informal Pat 6. ☐ Interview Summary (F Paper No./Mail Date 7. ☑ Examiner's Amendme 8. ☐ Examiner's Statement	PTO-413), · ent/Comment			
	of Biological Material 9.   Other					

Art Unit: 1631

### **DETAILED ACTION**

#### APPLICANTS' ARGUMENTS

Applicants' arguments, filed 7/12/04, have been fully considered and are deemed to be persuasive.

### **EXAMINER'S AMENDMENT**

Authorization for this Examiner's Amendment was given in a telephone interview with Thomas Kelley on August 10, 2004.

#### In the claims:

In claim 11, line 2, delete "comprising"; insert -of--.

In claim 43, line 3, inserting "nucleic acid" after "linked to a".

In claim 43, line 3, delete "having"; insert -of--.

In claim 44, line 2, delete "having"; insert -of--.

In claim 45, line 2, delete "comprising"; insert -of--.

## REASONS FOR ALLOWANCE

The following is an examiner's statement for reasons of allowance:

The invention is directed to a substantially purified nucleic acid molecule that encodes a nitrite reductase of SEQ ID NO: 11926 or a sequence of at least 70% or 90% sequence identity to SEQ ID NO: 11926 as well as recombinant DNA constructs and a plant cell containing such a

Application/Control Number: 09/902,540

Art Unit: 1631

nucleic acid molecule. The prior art does not disclose a substantially purified nucleic acid molecule that encodes a nitrite reductase of SEQ ID NO: 11926 or a sequence of at least 70% or 90% sequence identity to SEQ ID NO: 11926 as well as recombinant DNA constructs and a plant cell containing such a nucleic acid molecule, as they are claimed in the instant invention.

Any comments considered necessary by applicant must be submitted no later than the payment of the Issue Fee and, to avoid processing delays, should accompany the Issue Fee.

Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

#### **EXAMINER INFORMATION**

Papers related to this application may be submitted to Technical Center 1600 by facsimile transmission. Papers should be faxed to Technical Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform to the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993) (See 37 CFR §1.6(d)). The CM1 Fax Center number is (703) 872-9306.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carolyn Smith, whose telephone number is (571) 272-0721. The examiner can normally be reached Monday through Thursday from 8 A.M. to 6:30 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, can be reached on (571) 272-0722.

Application/Control Number: 09/902,540

Art Unit: 1631

Page 4

Any inquiry of a general nature or relating to the status of this application should be directed to Legal Instruments Examiner Tina Plunkett whose telephone number is (571) 272-0549.

August 10, 2004

Le lin I Mandel 8/13/04